文献速递神经核医学放射性药物与辐射防护

新型HDAC6放射性示踪剂[18F]EKZ-001在人脑中的临床验证

Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-07-08

这项首次人体PET研究评估了HDAC6选择性示踪剂[18F]EKZ-001在健康成人脑内的结合情况。四名健康受试者完成全身PET/CT生物分布与辐射剂量学,12名健康受试者完成120分钟动态PET/MR以确定最佳动力学模型,4名受试者完成重测。结果显示有效剂量为39.1±7.0 μSv/MBq,Logan图形分析为优选定量方法,男性多数脑区VT显著高于女性,未报告相关不良事件。

要点

  • 有效剂量为39.1±7.0 μSv/MBq,未报告相关不良事件
  • Logan图形分析VT与2TCM一致,绝对重测变异为7.7±4.9%
  • 男性在多数皮层和皮层下脑区VT显著高于女性

核心结论

  • [18F]EKZ-001安全且适用于定量人脑HDAC6表达,Logan图形分析为优选定量方法。
  • 男性全脑HDAC6表达高于女性。

研究设计与样本

  • 首次人体PET研究,生物分布与辐射剂量学在4名健康受试者(2男/2女,23.5±2.4岁)中采用连续全身PET/CT进行。
  • 最佳动力学模型在12名健康受试者(6男/6女,57.6±3.7岁)中通过120分钟动态PET/MR扫描确定,使用放射性代谢物校正的动脉血浆输入函数。
  • 4名受试者(2男/2女,57.3±5.6岁)以1天扫描间隔进行重测扫描以确定重测变异度(TRV)。

主要发现

  • 有效剂量为39.1±7.0 μSv/MBq。
  • 基于Akaike信息准则,2TCM优于1TCM。
  • 区域Logan图形分析VT与2TCM VT一致,但绝对TRV较低,为7.7±4.9%。
  • 区域VT值相对均匀,海马和内嗅皮层最高。
  • 通过0至60分钟扫描加90至120分钟扫描可实现采集时间缩短。

关键数值与推荐

  • 有效剂量为39.1±7.0 μSv/MBq。
  • 绝对TRV为7.7±4.9%。
  • 区域VT值相对均匀,最高值位于海马和内嗅皮层。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer's disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [18F]EKZ-001 ([18F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. METHODS: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (VT) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. VT differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. RESULTS: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA VT were in agreement with 2TCM VT, however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional VT values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher VT than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. CONCLUSION: [18F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Koole M, Van Weehaeghe D, Serdons K, et al. Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain. Eur J Nucl Med Mol Imaging. 2020. PMID: 32638097. doi:10.1007/s00259-020-04891-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。